PharmaStock – Sudarshan Pharma Expands Equity Base After Warrant Conversion
PharmaStock – Sudarshan Pharma Industries Limited has strengthened its capital structure after completing the conversion of preferential warrants into equity shares, a move that is expected to attract attention from investors monitoring developments in the pharmaceutical sector.
Mumbai-headquartered Sudarshan Pharma Industries Limited informed stock exchanges on June 12, 2026, that its Warrants Committee had approved the issuance of 90 lakh equity shares. The allotment was carried out following the conversion of warrants previously issued to members of the promoter group under a preferential allotment arrangement.
Equity Shares Issued Through Warrant Conversion
According to the company’s regulatory disclosure, the newly issued equity shares carry a face value of Re 1 each. The shares were allotted at an issue price of ₹16.983 per share, which includes a premium component of ₹15.983 per share. The conversion involved 9 lakh warrants that had originally been allotted to promoter-category investors.
The transaction was completed after the company received the remaining payment required for the conversion process. Under existing regulatory norms, warrant subscribers are required to deposit 25 percent of the total issue amount at the time of allotment, while the balance 75 percent must be paid when the warrants are converted into equity shares.
Promoter Group Members Increase Shareholding
The filing stated that promoter group members Vasantrai Hemal Mehta and Sachin Vasantrai Mehta participated equally in the conversion exercise. Each investor converted 4.5 lakh warrants, resulting in the allotment of 45 lakh equity shares to each of them.
The conversion has led to an increase in promoter participation within the company and reflects continued financial commitment from key stakeholders. Market observers often view such capital infusions from promoters as an indication of confidence in a company’s long-term business outlook.
Paid-Up Capital Sees Increase
Following the allotment of the new shares, Sudarshan Pharma’s paid-up equity capital has risen to ₹24.96 crore. The company’s capital base now consists of 24.96 crore equity shares with a face value of Re 1 each.
The company also clarified that the newly allotted shares will enjoy the same rights and benefits as the existing equity shares. This means they will rank equally with previously issued shares in matters relating to dividends, voting rights, and other shareholder entitlements.
Updated Shareholding Pattern Released
After the completion of the allotment process, the promoter and promoter group collectively hold 58.93 percent of the company’s equity. The remaining 41.07 percent is held by public and non-promoter shareholders.
The revised ownership structure highlights a stronger promoter presence in the company following the successful conversion of the warrants into equity shares. Such changes in shareholding patterns are often closely monitored by investors seeking insights into management confidence and future business expectations.
Market Participants Expected to Monitor Stock
The latest development is likely to remain a key point of interest for market participants in the coming trading sessions. The completion of the warrant conversion process, along with the increase in promoter ownership, may influence investor sentiment toward the stock.
Analysts and shareholders are expected to watch how the market responds to the enhanced promoter stake and the company’s strengthened equity position. The announcement adds another significant corporate update for Sudarshan Pharma as investors assess its future growth trajectory and capital management strategy.